Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study
- Jacob Sands
- , Myung Ju Ahn
- , Aaron Lisberg
- , Byoung Chul Cho
- , George Blumenschein
- , Elaine Shum
- , Elvire Pons Tostivint
- , Yasushi Goto
- , Kiyotaka Yoh
- , Rebecca Heist
- , Junichi Shimizu
- , Jong Seok Lee
- , Paul Baas
- , David Planchard
- , Maurice Pérol
- , Enriqueta Felip
- , Wu Chou Su
- , Hong Zebger-Gong
- , Lan Lan
- , Chelsea Liu
- Dana-Farber Cancer Institute
- University of California at Los Angeles
- Yonsei University
- University of Texas Health Science Center at Houston
- New York University
- Nantes University
- National Cancer Center Japan
- Harvard University
- Aichi Cancer Center Hospital and Research Institute
- Seoul National University
- Leiden University
- Gustave Roussy
- Université Paris-Saclay
- Centre Léon Bérard
- Autonomous University of Barcelona
- National Cheng Kung University
- Daiichi Sankyo Company, Limited
- Hospital Universitario 12 de Octubre
Research output: Contribution to journal › Article › peer-review
82
Link opens in a new tab
Scopus
citations